Fonseca reports Phase 3 success for new swimmer’s ear treatment

Fonseca Biosciences has reported positive pooled Phase 3 results for XTORO (finafloxacin), with the antibiotic demonstrating improved clinical cure, pathogen eradication and faster pain relief in patients with acute otitis externa.

The findings from two randomised clinical trials involving more than 1,200 patients have been published in Annals of Otology, Rhinology & Laryngology, providing peer-reviewed evidence for the FDA-approved treatment, which is now commercially available in the US.

Phase 3 trials demonstrate improved clinical cure

The two Phase 3 trials were conducted across 128 clinical sites in the US and Canada, enrolling paediatric and adult patients aged six months and older with acute otitis externa, commonly known as swimmer’s ear.

The studies compared finafloxacin otic suspension, at a concentration of 0.3%, with vehicle, assessing clinical cure, microbiological eradication and patient-reported ear pain.

In the pathogen-positive subset of the intention-to-treat population, 70.2% of patients receiving finafloxacin achieved clinical cure by day 11, compared with 36.6% in the vehicle group (P <0.0001).

Across the overall intention-to-treat population, clinical cure rates were 71% and 49.8%, respectively.

Finafloxacin also demonstrated higher eradication rates against the two most common bacterial pathogens associated with the infection. Eradication of Staphylococcus aureus reached 89%, compared with 39.2% for vehicle, while rates for Pseudomonas aeruginosa were 85.3% and 26.8%, respectively.

Treatment reduced time to ear pain relief

Patients receiving finafloxacin experienced a median time to cessation of ear pain of 3.5 days, compared with seven days for those receiving vehicle (P <0.0001).

Exploratory analyses also identified high pathogen eradication rates among clinically cured patients with organisms resistant to other fluoroquinolones.

Lead author and clinical investigator Ann Edmunds said: “The data from these two Phase 3 trials are noteworthy because they demonstrate consistency across the outcomes that matter most to clinicians and patients: high rates of pathogen eradication, including antibiotic-resistant organisms, and rapid relief from ear pain versus vehicle.”

Finafloxacin was generally well tolerated, with adverse events reported in 14.7% of patients receiving the treatment and 16.1% of those receiving vehicle.

XTORO now commercially available in the US

The publication adds to the evidence supporting XTORO, which Fonseca describes as the first new molecular entity approved for acute otitis externa in more than two decades.

The FDA-approved topical antibiotic is indicated for infections caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus in patients aged one year and older.

XTORO is now commercially available in the US following FDA approval of the Prior Approval Supplement required for commercial manufacturing.

Fonseca founder and chief executive officer Mike Luby said: “The publication of these Phase 3 results provides important peer-reviewed evidence supporting XTORO’s differentiated clinical profile.”

Mail Icon

news via inbox

Sign up for our newsletter and get the latest news right in your inbox